NASDAQ:RANI Rani Therapeutics (RANI) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free RANI Stock Alerts $6.68 +0.12 (+1.83%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$6.29▼$6.7050-Day Range$3.03▼$7.8552-Week Range$1.82▼$8.75Volume42,500 shsAverage Volume239,553 shsMarket Capitalization$335.05 millionP/E RatioN/ADividend YieldN/APrice Target$11.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Rani Therapeutics alerts: Email Address Rani Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside72.2% Upside$11.50 Price TargetShort InterestBearish14.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.94) to ($0.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.05 out of 5 starsMedical Sector562nd out of 914 stocksPharmaceutical Preparations Industry246th out of 418 stocks 3.5 Analyst's Opinion Consensus RatingRani Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRani Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.69% of the float of Rani Therapeutics has been sold short.Short Interest Ratio / Days to CoverRani Therapeutics has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.Change versus previous monthShort interest in Rani Therapeutics has recently decreased by 10.42%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRani Therapeutics does not currently pay a dividend.Dividend GrowthRani Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RANI. Previous Next 2.4 News and Social Media Coverage News SentimentRani Therapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Rani Therapeutics this week, compared to 2 articles on an average week.Search Interest17 people have searched for RANI on MarketBeat in the last 30 days. This is an increase of 750% compared to the previous 30 days.MarketBeat Follows6 people have added Rani Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rani Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders50.02% of the stock of Rani Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.19% of the stock of Rani Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rani Therapeutics are expected to grow in the coming year, from ($0.94) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rani Therapeutics is -5.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rani Therapeutics is -5.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRani Therapeutics has a P/B Ratio of 13.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Rani Therapeutics Stock (NASDAQ:RANI)Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.Read More RANI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RANI Stock News HeadlinesApril 23, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Corcept Therapeutics (CORT), Structure Therapeutics, Inc. Sponsored ADR (GPCR)April 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Astria Therapeutics (ATXS) and Aslan Pharmaceuticals (ASLN)April 27, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 18, 2024 | americanbankingnews.comRani Therapeutics (NASDAQ:RANI) Trading 14.3% Higher April 14, 2024 | seekingalpha.comRANI Rani Therapeutics Holdings, Inc.April 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Liquidia Technologies (LQDA) and Xtant Medical Holdings (XTNT)March 25, 2024 | markets.businessinsider.comBuy Rating for Rani Therapeutics: Promising Clinical Data and Significant Market PotentialMarch 22, 2024 | seekingalpha.comRani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call TranscriptApril 27, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. March 21, 2024 | msn.comRANI: 2023 ResultsMarch 21, 2024 | finance.yahoo.comQ4 2023 Rani Therapeutics Holdings Inc Earnings CallMarch 21, 2024 | finance.yahoo.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | investorplace.comRANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q4 2023March 20, 2024 | benzinga.comRecap: Rani Therapeutics Hldgs Q4 EarningsMarch 20, 2024 | globenewswire.comRani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate UpdateMarch 19, 2024 | benzinga.comEarnings Outlook For Rani Therapeutics HldgsMarch 16, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Verastem (VSTM), Akebia Therapeutics (AKBA)March 16, 2024 | finance.yahoo.comRANI Apr 2024 2.500 putMarch 15, 2024 | finance.yahoo.comRANI Apr 2024 5.000 putMarch 15, 2024 | globenewswire.comRani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial ResultsMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Incyte (INCY)March 12, 2024 | finance.yahoo.comIndividual investors own 40% of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shares but private companies control 47% of the companyFebruary 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Arcus Biosciences (RCUS) and United Therapeutics (UTHR)February 20, 2024 | finance.yahoo.comRANI: INITIATION – Realizing Oral Administration of BiologicsFebruary 19, 2024 | bizjournals.comSilicon Valley businesswomen share thoughts on mentoringFebruary 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rani Therapeutics Holdings on Strong Clinical and Strategic ProspectsFebruary 6, 2024 | msn.comRani Therapeutics Reports Positive Phase 1 Trial OutcomesSee More Headlines Receive RANI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today4/27/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RANI CUSIPN/A CIK1856725 Webwww.ranitherapeutics.com Phone408-457-3700FaxN/AEmployees140Year FoundedN/APrice Target and Rating Average Stock Price Target$11.50 High Stock Price Target$17.00 Low Stock Price Target$8.00 Potential Upside/Downside+72.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-79.92% Return on Assets-44.08% Debt Debt-to-Equity Ratio0.96 Current Ratio6.36 Quick Ratio6.36 Sales & Book Value Annual Sales$2.72 million Price / Sales123.18 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book13.10Miscellaneous Outstanding Shares50,157,000Free Float25,068,000Market Cap$335.05 million OptionableOptionable Beta0.92 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Talat Imran (Age 42)CEO & Director Comp: $827kMr. Svai S. Sanford (Age 54)Chief Financial Officer Comp: $661.6kDr. Mir Hashim (Age 64)Chief Scientific Officer Comp: $661.6kMr. Eric Groen (Age 53)General Counsel Ms. Bella VazquezVice President of Human ResourcesMs. Kate McKinley M.B.A.Chief Business OfficerMs. Arvinder DhallaVice President of Clinical DevelopmentMore ExecutivesKey CompetitorsUroGen PharmaNASDAQ:URGNAtai Life SciencesNASDAQ:ATAIMereo BioPharma GroupNASDAQ:MREOPrecigenNASDAQ:PGENAtea PharmaceuticalsNASDAQ:AVIRView All CompetitorsInsiders & InstitutionsAlpha Square Group S LLCSold 28,000 shares on 2/14/2024Ownership: 0.118%Simplex Trading LLCBought 100 shares on 2/2/2024Ownership: 0.000%Talat ImranBought 10,000 shares on 12/6/2023Total: $22,700.00 ($2.27/share)Talat ImranBought 5,000 shares on 12/4/2023Total: $12,850.00 ($2.57/share)Talat ImranBought 20,000 shares on 11/29/2023Total: $41,000.00 ($2.05/share)View All Insider TransactionsView All Institutional Transactions RANI Stock Analysis - Frequently Asked Questions Should I buy or sell Rani Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rani Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RANI shares. View RANI analyst ratings or view top-rated stocks. What is Rani Therapeutics' stock price target for 2024? 5 brokers have issued 1 year price targets for Rani Therapeutics' shares. Their RANI share price targets range from $8.00 to $17.00. On average, they anticipate the company's share price to reach $11.50 in the next twelve months. This suggests a possible upside of 72.2% from the stock's current price. View analysts price targets for RANI or view top-rated stocks among Wall Street analysts. How have RANI shares performed in 2024? Rani Therapeutics' stock was trading at $3.32 at the beginning of 2024. Since then, RANI stock has increased by 101.2% and is now trading at $6.68. View the best growth stocks for 2024 here. When is Rani Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our RANI earnings forecast. How were Rani Therapeutics' earnings last quarter? Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) posted its quarterly earnings data on Wednesday, March, 20th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.04. When did Rani Therapeutics IPO? Rani Therapeutics (RANI) raised $100 million in an initial public offering on Friday, July 30th 2021. The company issued 6,666,667 shares at a price of $14.00-$16.00 per share. How do I buy shares of Rani Therapeutics? Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RANI) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
